Avid Bioservices Inc (CDMO)

[freethemice]

Next event Dec 5 at IBC Antibody Therapeutics meeting in San Diego
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79650678
Lets hope that Shan actually has something new to talk about.

Philip Thorpe (Univ. of Texas SW Medical Ctr) will give an update on the mechanism of anti-tumor action of bavituximab, an immunostimulatory chimeric monoclonal antibody that is showing promising activity in clinical trials in patients with various types of cancer. Bavituximab targets the immunosuppressive lipid phosphatidylserine (PS) that becomes exposed on tumor blood vessels and tumor cells. Tumors externalize PS and secrete PS-expressing exosomes that impose quiescence on immune cells, thereby creating a tumor microenvironment that supports tumor growth. Bavituximab causes myeloid-derived suppressor cells in tumors to differentiate into tumoricidal M1 macrophages that destroy tumor vasculature and tumor cells by antibody-dependent cell-mediated cytotoxicity. It also causes immature dendritic cells in tumors to mature and present tumor antigens that result in the generation of tumor-specific cytotoxic T cells. Thus, bavituximab reactivates innate & adaptive tumor immunity, and induces an immune cell-mediated shutdown of tumor vasculature. Joseph Shan (Peregrine Pharm.) will then give an update on the performance of bavituximab in clinical trials in patients with cancer. Bavituximab has been shown to be well-tolerated both as a single agent and in combination with approved therapies. Bavituximab has demonstrated promising anti-tumor activity as an adjunct to std. chemotherapy, and is advancing to late stage clinical development in NSCLC.